Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Gilead Sciences, Inc. or Bristol-Myers Squibb Company because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Gilead Sciences, Inc. and Bristol-Myers Squibb Company compare based on key financial metrics to determine which better meets your investment needs.

About Gilead Sciences, Inc. and Bristol-Myers Squibb Company

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Latest Biotechnology and Gilead Sciences, Inc., Bristol-Myers Squibb Company Stock News

As of September 2, 2026, Gilead Sciences, Inc. had a $185.5 billion market capitalization, compared to the Biotechnology median of $288.9 million. Gilead Sciences, Inc.’s stock is up 22.3% in 2026, up 0.8% in the previous five trading days and up 32.74% in the past year.

Currently, Gilead Sciences, Inc. does not have a price-earnings ratio. Gilead Sciences, Inc.’s trailing 12-month revenue is $30.5 billion with a -10.6% net profit margin. Year-over-year quarterly sales growth most recently was 10.2%. Analysts expect adjusted earnings to reach $-0.431 per share for the current fiscal year. Gilead Sciences, Inc. currently has a 2.2% dividend yield.

As of September 2, 2026, Bristol-Myers Squibb Company had a $138.2 billion market cap, putting it in the 98th percentile of all stocks. Bristol-Myers Squibb Company’s stock is up 25.3% in 2026, up 0.9% in the previous five trading days and up 42.71% in the past year.

Currently, Bristol-Myers Squibb Company’s price-earnings ratio is 14.9. Bristol-Myers Squibb Company’s trailing 12-month revenue is $49.2 billion with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was 5.7%. Analysts expect adjusted earnings to reach $6.949 per share for the current fiscal year. Bristol-Myers Squibb Company currently has a 3.7% dividend yield.

How We Compare Gilead Sciences, Inc. and Bristol-Myers Squibb Company Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Gilead Sciences, Inc. and Bristol-Myers Squibb Company’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Gilead Sciences, Inc. and Bristol-Myers Squibb Company Stock Value Grades

Company	Ticker	Value
Gilead Sciences, Inc.	GILD	D
Bristol-Myers Squibb Company	BMY	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Gilead Sciences, Inc. has a Value Score of 28, which is Expensive. Bristol-Myers Squibb Company has a Value Score of 51, which is Average.

The Value Stock Winner: No Clear Winner

Neither Gilead Sciences, Inc. or Bristol-Myers Squibb Company has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Gilead Sciences, Inc. or Bristol-Myers Squibb Company is the better investment when it comes to value.

Gilead Sciences, Inc. and Bristol-Myers Squibb Company Growth Grades

Company	Ticker	Growth
Gilead Sciences, Inc.	GILD	C
Bristol-Myers Squibb Company	BMY	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Gilead Sciences, Inc. has a Growth Score of 56, which is Average. Bristol-Myers Squibb Company has a Growth Score of 43, which is Average.

The Growth Stock Winner: No Clear Winner

Neither Gilead Sciences, Inc. or Bristol-Myers Squibb Company has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Gilead Sciences, Inc. or Bristol-Myers Squibb Company is the better investment when it comes to sustainable growth.

Gilead Sciences, Inc. and Bristol-Myers Squibb Company’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Gilead Sciences, Inc.	GILD	B
Bristol-Myers Squibb Company	BMY	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Gilead Sciences, Inc. has a Earnings Estimate Score of 75, which is Positive. Bristol-Myers Squibb Company has a Earnings Estimate Score of 77, which is Positive.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both Gilead Sciences, Inc. and Bristol-Myers Squibb Company have a grade of B. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether Gilead Sciences, Inc. or Bristol-Myers Squibb Company is a better fit.

Other Gilead Sciences, Inc. and Bristol-Myers Squibb Company Grades

In addition to Value, Growth and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Gilead Sciences, Inc. and Bristol-Myers Squibb Company pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Gilead Sciences, Inc. or Bristol-Myers Squibb Company Stock?

Overall, Gilead Sciences, Inc. stock has a Value Score of 28, Growth Score of 56 and Estimate Revisions Score of 75.

Bristol-Myers Squibb Company stock has a Value Score of 51, Growth Score of 43 and Estimate Revisions Score of 77.

Comparing Gilead Sciences, Inc. and Bristol-Myers Squibb Company’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.